Ovarian Cancer (ASCO) Basic Listing

Updates in Ovarian Cancer

From the ASCO Annual Meeting

Mostafa Eyada, MD, University of Texas, Medical Branch

Videos

Bevacizumab Plus Oral Cyclophosphamide Demonstrated Safety, Efficacy Among Patients With Recurrent Platinum-Resistant Ovarian Cancer

06/19/2024

Mostafa Eyada, MD

Mostafa Eyada, MD, describes a retrospective analysis assessing the safety and efficacy of bevacizumab plus oral cyclophosphamide among patients with recurrent high-grade platinum-resistant ovarian, fallopian tube, and primary peritoneal...

Mostafa Eyada, MD, describes a...

06/19/2024

Oncology

Frederik Marmé, PhD, Heidelberg University

Videos

Atezolizumab Plus Chemotherapy and Bevacizumab Did Not Improve Survival For Patients With Recurrent Platinum-Resistant Ovarian Cancer

06/13/2024

Frederik Marmé, MD, PhD

According to phase 3 data, the addition of atezolizumab to the standard regiment of bevacizumab plus non-platinum chemotherapy did not improve overall survival or progression-free survival among patients with recurrent platinum-resistant...

According to phase 3 data, the...

06/13/2024

Oncology

Conference Coverage

Batiraxcept Plus Paclitaxel for Patients With Platinum-Resistant Ovarian Cancer

06/13/2024

Allison Casey ;

According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.

According to phase 2 results,...

06/13/2024

Oncology

Conference Coverage

Suvemcitug Plus Chemotherapy Improved Survival Outcomes Among Patients With Platinum-Resistant Ovarian Cancer

06/13/2024

Allison Casey ;

Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.

Results from the phase 3 SCORES...

06/13/2024

Oncology

Conference Coverage

Ceralasertib Plus Olaparib Demonstrated Promising Clinical Activity Among Patients With Recurrent Platinum-Sensitive Ovarian Cancer

06/04/2024

Stephanie Holland

Results from a phase 2 study found that ceralasertib plus olaparib was well tolerated and demonstrated promising clinical activity among patients with recurrent platinum-sensitive ovarian cancer, regardless of tumor genomic instability.

Results from a phase 2 study...

06/04/2024

Oncology

Conference Coverage

Olaparib Alone As a Chemotherapy-Free Approach Post-Cytoreduction for Patients With Platinum-Sensitive High-Grade Serous Ovarian Cancer

06/03/2024

Allison Casey ;

According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...

According to phase 2 data to be...

06/03/2024

Oncology

Kathleen Moore, MD, Stephenson Cancer Center

Videos

Mirvetuximab Soravtansine Improved Overall Survival for Patients With Folate Receptor Alpha-High Platinum-Resistant Ovarian Cancer

07/27/2023

At the 2023 ASCO Annual Meeting, Kathleen Moore, MD, shares results from the MIRASOL trial, evaluating mirvetuximab soravtansine among patients with folate recetor alpha-high platinum-resistant ovarian cancer.

At the 2023 ASCO Annual Meeting,...

07/27/2023

Oncology

Debra Richardson, MD, Stephenson Cancer Center

Videos

Real-World Effectiveness of PARP Inhibitor Maintenance Therapy for Patients With Advanced Ovarian Cancer

06/21/2023

Debra Richardson, MD, discusses results from a real-world analysis exploring the effectiveness of PARP inhibitor maintenance therapy in patients with advanced ovarian cancer, specifically defined by biomarker status.

Debra Richardson, MD, discusses...

06/21/2023

Oncology

Helene Blons, PhD, PharmD, Georges Pompidou Hospital

Videos

Impact of BRCA1 and RAD15 Methylation on Maintenance Olaparib Plus Bevacizumab Efficacy in Ovarian Cancer

06/16/2023

At the 2023 ASCO Annual Meeting, Helene Blons, PhD, PharmD, discusses results from an abstract addressing the impact of BRCA1 and RAD51 methylation on the efficacy of olaparib plus bevacizumab maintenance treatment, from the...

At the 2023 ASCO Annual Meeting,...

06/16/2023

Oncology

Conference Coverage

Durvalumab Plus Chemotherapy and Bevacizumab Followed By Triplet Maintenance in Newly Diagnosed Advanced Ovarian Cancer

06/15/2023

Amber Denham ;

Phase 3 data reveal treatment with durvalumab plus paclitaxel/carboplatin and bevacizumab followed by maintenance bevacizumab with durvalumab and olaparib significantly improves PFS in patients with newly diagnosed ovarian cancer without a...

Phase 3 data reveal treatment...

06/15/2023

Oncology

Recent News

Conference Coverage

Ceralasertib Plus Olaparib Demonstrated Promising Clinical Activity Among Patients With Recurrent Platinum-Sensitive Ovarian Cancer

06/04/2024

Stephanie Holland

Results from a phase 2 study...

06/04/2024

Oncology

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology